Hyo Seop Ahn

Hyo Seop Ahn

Auto-generated profile, based on publicly available information

Hyo Seop Ahn

Department of Pediatrics, Seoul National University College of Medicine, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2009 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
JLJ W Lee
J W Lee
HKH J Kang
H J Kang
EKE K Kim
E K Kim
HKH Kim
H Kim
HSH Y Shin
H Y Shin
HAH S Ahn
H S Ahn

23 May 2019 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
THThe Hereditary Hemolytic Anemia Working Party Of The Korean Society Of Hematology
The Hereditary Hemolytic Anemia Working Party Of The Korean Society Of Hematology
HCHyoung Soo Choi
Hyoung Soo Choi
QCQute Choi
Qute Choi
JKJung-Ah Kim
Jung-Ah Kim
KIKyong Ok Im
Kyong Ok Im
DLDong-Soon Lee
Dong-Soon Lee
Current diagnostic tests for hereditary spherocytosis (HS) focus on the detection of hemolysis or indirectly assessing defects of membrane protein, whereas direct methods to detect protein defects are complicated and difficult to implement. In the present study, we investigated the patterns of genetic variation associated with HS among patients clinically diagnosed with HS. Multi-gene targeted sequencing of 43 genes (17 RBC membrane protein-encoding genes, 20 RBC enzyme-encoding genes, and six additional genes for the differential diagnosis) was performed using the Illumina HiSeq platform. Among 59 patients with HS, 50 (84.7%) had one or more significant variants in a RBC membrane protein-encoding genes. A total of 54 significant variants including 46 novel mutations were detected in six RBC membrane protein-encoding genes, with the highest number of variants found in SPTB (n = 28), and followed by ANK1 (n = 19), SLC4A1 (n = 3), SPTA1 (n = 2), EPB41 (n = 1), and EPB42 (n = 1). Concurrent mutations of genes encoding RBC enzymes (ALDOB, GAPDH, and GSR) were detected in three patients. UGT1A1 mutations were present in 24 patients (40.7%). Positive rate of osmotic fragility test was 86.8% among patients harboring HS-related gene mutations. This constitutes the first large-scaled genetic study of Korean patients with HS. We demonstrated that multi-gene target sequencing is sensitive and feasible that can be used as a powerful tool for diagnosing HS. Considering the discrepancies of clinical and molecular diagnoses of HS, our findings suggest that molecular genetic analysis is required for accurate diagnosis of HS.

24 April 2013 in Pediatric Hematology and Oncology
Verified
Journal Article
Closed access
JLJi Won Lee
Ji Won Lee
HSHee Young Shin
Hee Young Shin
HKHyoung Jin Kang
Hyoung Jin Kang
HKHyery Kim
Hyery Kim
JPJune Dong Park
June Dong Park
HAHyo Seop Ahn
Hyo Seop Ahn
Langerhans cell histiocytosis (LCH) is a rare disease of unknown etiology. Large studies by single institutions have been infrequent because of the rarity of the disease and the diversity of clinical manifestations. In this study, the clinical characteristics, prognostic factors, and treatment outcomes were analyzed. Medical records were analyzed retrospectively for the 154 patients diagnosed and treated with LCH at Seoul National University Children's Hospital from January 1986 to December 2007. A total of 154 patients were evaluated. One hundred and six patients (68.8%) had single system disease, 48 patients (31.2%) had multisystem disease. Twenty-nine patients (18.8%) had risk organ involvement. Twenty-nine patients (18.8%) relapsed and the overall survival (OS) of the total study population was 97.1% with a median follow-up period of 7.0 years. Patients less than 4 years old, with involvement more than 2 organs and with risk organ involvement showed lower progression free survival (PFS) (P = .001, <.001, and <.001, respectively). Estimated 10-year PFS of patients with and without risk organ involvement were 52.6% and 83.8%, respectively. Patients with single system LCH had excellent prognosis showing 89.6% of PFS and 100% of OS. Patients with multisystem LCH also had a high survival rate, although the incidences of relapse remain to be solved. A new strategy to decrease the incidence of relapse is needed.

19 June 2006 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
HKH J Kang
H J Kang
SKS H Kho
S H Kho
MJM K Jang
M K Jang
SLS H Lee
S H Lee
HSH Y Shin
H Y Shin
HAH S Ahn
H S Ahn

25 August 2005 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
HSHee Young Shin
Hee Young Shin
HKHyoung Jin Kang
Hyoung Jin Kang
EPEun Sil Park
Eun Sil Park
HCHyoung Soo Choi
Hyoung Soo Choi
HAHyo Seop Ahn
Hyo Seop Ahn
YCYong Mook Choi
Yong Mook Choi

1 January 2010 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JPJun Eun Park
Jun Eun Park
JKJoseph Kang
Joseph Kang
KYKeon Hee Yoo
Keon Hee Yoo
KSKi Woong Sung
Ki Woong Sung
HKHong Hoe Koo
Hong Hoe Koo
HAHyo Seop Ahn
Hyo Seop Ahn
Park JE, et al. J Korean Med Sci. 2010 Aug;25(8):1160-1166. http://dx.doi.org/10.3346/jkms.2010.25.8.1160